Search the Newsreel

Marriott Vacations (NYSE:VAC) Posts Better-Than-Expected Sales In Q2 CY2026

Harbour Energy (LSE:HBR) and Ithaca Energy (LSE:ITH) Reflect North Sea Risk

Arcosa (NYSE: ACA) reports Q2 2026 results and $150 per share CRH buyout

Arcosa, Inc. reported its Q2 2026 results, with revenues up 2% year-over-year to $658.7 million and Adjusted EBITDA increasing 5% to $145.9 million. The company is set to be acquired by CRH for $150 per share in an all-cash transaction, expected to close in …

Acacia Research (ACTG) Stock Drifts As Licensing Windfall Leaves Profit Flat

Earnings Flash (VAC) Marriott Vacations Worldwide Corporation Posts Q2 Adjusted EPS $2.31 per Share, vs. FactSet Est of $1.97

Marriott Vacations Worldwide Corporation (VAC) announced its Q2 adjusted EPS of $2.31 per share, surpassing FactSet's estimate of $1.97. The company's shares rose following this positive earnings report, with revenue also increasing in the second quarter. Marriott Vacations Worldwide has also updated its earnings …

Marriott Vacations Worldwide Reports Second Quarter 2026 Financial Results

ORLANDO, Fla., August 06, 2026--(BUSINESS WIRE)--Marriott Vacations Worldwide Corporation (NYSE: VAC) ("MVW," the "Company," "we" or "our") reported financial results for the second quarter of 2026. Second Quarter 2026 Highlights Contract sales increased 22% year over year to $545 million in the quarter. Net …

5 Revealing Analyst Questions From Hilton Grand Vacations’s Q2 Earnings Call

Acadian Asset Management (AAMI) On Strong Q2 Results, Is The Valuation Still Justified?

Marriot Vacations Worldwide earnings beat by $0.36, revenue topped estimates

Arcosa misses top-line and bottom-line estimates; suspends FY26 outlook

* Arcosa press release [https://seekingalpha.com/pr/20608903-arcosa-inc-announces-second-quarter-2026-results] (ACA [https://seekingalpha.com/symbol/ACA]): Q2 Non-GAAP EPS of $1.13 misses by $0.05. * Revenue of $658.7M (+1.7% Y/Y) misses by $27.4M. * Operating cash flow from continuing operations was $(24.7) million compared to $38.0 million in the prior period. * Capital …

Is Academy Sports And Outdoors (ASO) Undervalued After Its Buy Rating And Retail Media Launch?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Academy Sports and Outdoors stock has delivered a 40.9% gain over the past five years, yet recent share price softness and a strong …

Arcosa (ACA) Q2 Earnings and Revenues Lag Estimates

Arcosa (ACA) came out with quarterly earnings of $1.13 per share, missing the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Here's What Key Metrics Tell Us About Arcosa (ACA) Q2 Earnings

For the quarter ended June 2026, Arcosa (ACA) reported revenue of $658.7 million, down 10.6% over the same period last year. EPS came in at $1.13, compared to $1.27 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $687.35 …

ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus

ACADIA Pharmaceuticals (ACAD) saw its stock jump 6.1% after strong Q2 2026 earnings, reporting increased revenue and net income. The article highlights a significant valuation gap with a P/E of 13 against a discounted cash flow estimate of US$87.67 per share, suggesting potential for …

Arcosa: Q2 Earnings Snapshot

Arcosa Inc. (ACA) reported strong second-quarter results, with net income of $328.5 million, or $6.67 per share. Adjusted earnings reached $1.13 per share, and the company's revenue for the period was $658.7 million. Arcosa's shares have seen significant growth, increasing 37% year-to-date and 71% …

ACADIA PHARMACEUTICALS INC Quarterly Earnings Report

ACADIA PHARMACEUTICALS INC (ACAD) has released its unaudited quarterly earnings report for the three and six months ended June 30, 2026. The company reported sufficient liquidity to fund planned operations beyond the next 12 months with $956.5 million in cash, cash equivalents, and investment …

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $33.25, Implies 22% Upside

ACADIA Pharmaceuticals Inc.'s average stock price target has been raised from $32.95 to $33.25 by 20 analysts, with a range of $17 to $45 per share. This new target implies a potential upside of approximately 22% based on the August 4 closing price. The …

Acadia Realty Trust Keeps Quarterly Dividend at $0.20 a Share, Payable Oct. 15 to Holders of Record Sept. 30

Acadia Realty Trust has announced that it will maintain its quarterly dividend at $0.20 per share. This dividend is scheduled to be paid on October 15 to shareholders who are on record as of September 30. The announcement was made on August 5, 2026.

Earnings Flash (ADN.TO) Acadian Timber Corp. Reports Q2 Revenue C$14.6M

Acacia Research (NASDAQ:ACTG) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS

Arcosa stock rises on pending CRH acquisition despite Q2 miss

Arcosa Inc. reported Q2 results that missed Wall Street expectations, with adjusted EPS of $1.13 and revenue of $658.7 million. Despite the miss, the stock rose 2.5% in after-hours trading, likely due to investor focus on the pending $150 per share acquisition by CRH, …

ACADIA PHARMACEUTICALS INC SEC Filing (Aug 5, 2026)

This article reports on an SEC Form 144 filing by ACADIA PHARMACEUTICALS INC (ACAD) on August 5, 2026, indicating a proposed sale of 5849 shares of common stock acquired through a stock option exercise, with an aggregate market value of $158,800.35, to be sold …

Earnings call transcript: Acacia Research Q2 2026 revenue jumps on licensing win

BRIEF-Arcosa Q2 Revenue USD 658.7 Million Vs. IBES Estimate USD 687.5 Million

Arcosa reported Q2 revenue of $658.7 million, falling short of the IBES estimate of $687.5 million. This brief financial update provides key figures for the company's second-quarter performance.

Earnings Flash (ACA) Arcosa, Inc. Posts Q2 Adjusted EPS $1.13 per Share, vs. FactSet Est of $1.21

Arcosa, Inc. (ACA) reported its Q2 adjusted EPS at $1.13 per share, falling short of the FactSet estimate of $1.21. The company also reported Q2 revenue of $658.7 million, which was below the FactSet estimate of $687.5 million. This financial update indicates that Arcosa's …

Press Release: Arcosa, Inc. Announces Second Quarter 2026 Results

Arcosa, Inc. announced its financial results for the second quarter of 2026. The press release details the company's performance, including revenues, net income, and earnings per share for the period. Further information regarding these results is expected within the document.

ACADIA Pharmaceuticals Inc. Revenue Breakdown – BMV:ACAD

ACADIA Pharmaceuticals Inc. (BMV:ACAD) generated 19.32 billion MXN in revenue last year, primarily from its Innovative Medicines segment. The United States was the largest contributor to this revenue, accounting for the entire 19.32 billion MXN. This revenue figure is a slight decrease from the …

Acacia Research earnings beat by $0.22, revenue topped estimates

Acacia Research (NASDAQ: ACTG) reported second-quarter EPS of $0.130, significantly exceeding analyst estimates of $-0.090 by $0.22. The company's revenue for the quarter also surpassed expectations, reaching $114.5 million against a consensus estimate of $50 million. Despite recent positive EPS revisions, the stock closed …

Marriott Vacations faces earnings test after Q1 stumble By Investing.com

Acacia Research (ACTG) Q2 2026 Earnings: Revenue Soars 124% to $114.6M, Strong IP Licensing Drives Growth

Acacia Research Corporation reported strong Q2 2026 results, with revenue soaring 124% to $114.6 million, primarily driven by a dramatic increase in intellectual property licensing revenue. The company achieved an adjusted net income of $12.8 million and maintained a robust balance sheet with no …

Hilton Grand Vacations (HGV) Gets a Buy from Deutsche Bank

Deutsche Bank has maintained a Buy rating on Hilton Grand Vacations (HGV) with a price target of $62.00. This follows a similar Buy rating from Mizuho Securities, although Bank of America Securities maintained a Hold rating. The article also notes negative insider sentiment, with …

RBC Capital raises Acadia Pharmaceuticals price target on strong Daybue sales

RBC Capital has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $37 from $36, maintaining an Outperform rating, due to better-than-expected Daybue sales. The company's strong performance, including $125 million in Daybue sales and solid Nuplazid performance, led to an increase in …

Acadia Pharmaceuticals stock hits 52-week high at 28.4 USD

Acadia Pharmaceuticals Inc. (ACAD) stock reached a new 52-week high of $28.35, currently trading at $28.92, reflecting a 19.75% increase over the past year. InvestingPro analysis suggests the stock is undervalued, boasting an attractive P/E ratio of 12.23 and a low PEG ratio of …

Holcim seeks more time for Cementos Pacasmayo (CPAC) share tender offer

Holcim Ltd. has requested an extension from Peru's Superintendence of the Securities Market (SMV) to commence its tender offer for Cementos Pacasmayo (CPAC) common shares. The extension is sought because the valuation entity, responsible for determining the minimum offer price, has not yet been …

Arcosa Inc (ACA) reaches earnings day after 11.7% 12-week rise

The infrastructure-products company reports as weekly indicators remain constructive, but recent gains and turnover show a restrained setup.

ACADIA Pharmaceuticals Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2026-08-05

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $0.18, beating estimates by $0.14, and revenue of $307.96 million, a 16.40% year-over-year increase, surpassing expectations by $12.44 million. This presentation provides investors …